Building off of research from David Liu's lab at Harvard, Nvelop Therapeutics is developing a platform for generation of customizable, non-viral particles for efficient delivery of gene therapies. Nvelop's particles are designed for selective and programmable targeting to specific cell and tissue types, high in vivo delivery efficiency, and full humanization. Nvelop aims to overcome the major lack of safe and effective in vivo delivery technologies so that more "undruggable" diseases can be treated.

<p>Nvelop Therapeutics is a stealth-mode biotechnology company founded in 2022. While the exact scientific focus of the company has not yet been revealed, Nvelop generally aims to develop a variety of novel therapeutic delivery technologies, with an initial focus on gene editing therapies. The founders of Nvelop Therapeutics include Professor David Liu (HHMI, Broad and Harvard) and Professor Keith Joung (MGH and Harvard). Nvelop has received initial funding from life science venture capital firms including Newpath Partners, Atlas Venture, and F-Prime Capital.</p>


Nvelop Therapeutics

Founded: 2022
Location: Cambridge, MA
Employee range: 51 - 100
Funding: 100M

Nvelop Therapeutics

Short description:

Drug notes:

Long description:

Jobs: